Long Pulse 1064 nm Nd:YAG Laser in the Treatment of Erythematotelangiectatic Rosacea and Other Erythematous Telangiectatic Facial Conditions

The goal of this clinical study is to assess the effectiveness of Nd:YAG laser 1064 nm in the long pulse mode in the treatment of signs of rosacea including the erythema of the face and telangiectasia. The used parameter of this laser was of very low energy (spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 millijoules (mJ) and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval) and also its was expected to have minimal adverse effects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rosacea, Erythematotelangiectatic Rosacea Skin Diseases Skin and Connective Tissue Diseases

Age range

32 year–52 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hawler Medical University

Erbil, 44001, Iraq

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient with rosacea (erythemato-telangiectatic type)

Exclusion criteria

Other clinical types of rosacea
Pregnancy and lactation in females
History of malignancies
History of photosensitivity
History of any other modalities of treatment of rosacea over last 6 months

Treatment and study plan

Nd:YAG laser 1064 nm

Device

The entire face of each patient with rosacea was treated with long-pulse 1064nm Nd:YAG laser. The parameters that been used were spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval.

Primary outcomes

Changes in erythema of face of patients with rosacea been treated by ND:YAG laser 1064 nm long pulse width by using clinician erythema scale (CEA)

Time frame: Three months

Erythema was graded from 0 to 4 using clinician erythema assessment scale (CEA). The score 0 is the lowest score of erythema and score 4 means the highest severity of erythema of the skin

Sponsors and collaborators

Lead sponsor

Hawler Medical University

Other

Registry information

Acronym: Nd:YAG

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2024
First posted: Apr 3, 2025
Registry last updated: Apr 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed